GSK4396687 / CureVac, GSK - LARVOL DELTA

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=98 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | N=180 ➔ 98

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. (PubMed, Vaccines (Basel)) - P1 | "Here, we report preclinical data for a lipid nanoparticle (LNP)-formulated RNActive N1-methylpseudouridine (N1mΨ) modified mRNA vaccine (CV0501) based on our second-generation SARS-CoV-2 vaccine CV2CoV, encoding the S protein of Omicron BA.1. Monovalent CV0501 significantly reduced SARS-CoV-2 BA.2 viral loads in the airways, demonstrating protection induced by CV0501 vaccination. CV0501 has now advanced into human Phase 1 clinical trials (ClinicalTrials.gov Identifier: NCT05477186)."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=180 | Active, not recruiting | Sponsor: GlaxoSmithKline | Initiation date: Mar 2021 ➔ Mar 2022

Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=180 | Active, not recruiting | Sponsor: GlaxoSmithKline | Initiation date: Mar 2022 ➔ Mar 2021

Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=180 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Apr 2023 | Trial primary completion date: Jul 2023 ➔ Apr 2023

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. (PubMed, Vaccines (Basel)) - "Significant cross-neutralisation of the SARS-CoV-2 variants, Alpha (B.1.1.7), Beta (B.1.351), and the 'mink' variant (B1.1.298) that were circulating at the time in early 2021 were also demonstrated. In addition, CV2CoV induced higher levels of antibodies at lower doses than CVnCoV, suggesting that dose-sparing could be possible with the next-generation SARS-CoV-2 vaccine, which could improve worldwide vaccine supply."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=210 | Recruiting | Sponsor: GlaxoSmithKline | Trial primary completion date: Mar 2023 ➔ Jul 2023

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=210 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (clinicaltrials.gov) - P1 | N=210 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases